Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Revenue
Samsung Biologics Co Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Revenue
₩3.7T
|
CAGR 3-Years
47%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Revenue
₩3.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Revenue
₩52.8B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Revenue
₩285B
|
CAGR 3-Years
32%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Revenue
₩14B
|
CAGR 3-Years
8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Revenue
₩34.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
45%
|
See Also
What is Samsung Biologics Co Ltd's Revenue?
Revenue
3.7T
KRW
Based on the financial report for Dec 31, 2023, Samsung Biologics Co Ltd's Revenue amounts to 3.7T KRW.
What is Samsung Biologics Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
47%
Over the last year, the Revenue growth was 23%. The average annual Revenue growth rates for Samsung Biologics Co Ltd have been 47% over the past three years , 47% over the past five years .